The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global GLP-1 Agonist Injection Market Research Report 2025
Synopsis
GLP-1 (glucagon-like peptide-1) agonists are a class of medications that mainly help manage blood sugar (glucose) levels in people with Type 2 diabetes. Some GLP-1 agonists can also help treat obesity. GLP-1 agonist medicines include injections and oral medications.
The global GLP-1 Agonist Injection market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
North American market for GLP-1 Agonist Injection is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for GLP-1 Agonist Injection is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of GLP-1 Agonist Injection include Novo Nordisk, Eli Lilly, AstraZeneca, GSK, Sanofi, Amylin, Huadong Medicine, Shanghai Benemae Pharmaceutical Corporation, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for GLP-1 Agonist Injection, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding GLP-1 Agonist Injection.
The GLP-1 Agonist Injection market size, estimations, and forecasts are provided in terms of sales volume (K Dose) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global GLP-1 Agonist Injection market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the GLP-1 Agonist Injection manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Novo Nordisk
Eli Lilly
AstraZeneca
GSK
Sanofi
Amylin
Huadong Medicine
Shanghai Benemae Pharmaceutical Corporation
Segment by Type
Short-acting Preparations
Long-acting Preparations
Segment by Application
Diabetes
Obesity
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of GLP-1 Agonist Injection manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of GLP-1 Agonist Injection in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
GLP-1 (glucagon-like peptide-1) agonists are a class of medications that mainly help manage blood sugar (glucose) levels in people with Type 2 diabetes. Some GLP-1 agonists can also help treat obesity. GLP-1 agonist medicines include injections and oral medications.
The global GLP-1 Agonist Injection market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
North American market for GLP-1 Agonist Injection is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for GLP-1 Agonist Injection is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of GLP-1 Agonist Injection include Novo Nordisk, Eli Lilly, AstraZeneca, GSK, Sanofi, Amylin, Huadong Medicine, Shanghai Benemae Pharmaceutical Corporation, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for GLP-1 Agonist Injection, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding GLP-1 Agonist Injection.
The GLP-1 Agonist Injection market size, estimations, and forecasts are provided in terms of sales volume (K Dose) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global GLP-1 Agonist Injection market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the GLP-1 Agonist Injection manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Novo Nordisk
Eli Lilly
AstraZeneca
GSK
Sanofi
Amylin
Huadong Medicine
Shanghai Benemae Pharmaceutical Corporation
Segment by Type
Short-acting Preparations
Long-acting Preparations
Segment by Application
Diabetes
Obesity
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of GLP-1 Agonist Injection manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of GLP-1 Agonist Injection in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 GLP-1 Agonist Injection Market Overview
1.1 Product Definition
1.2 GLP-1 Agonist Injection by Type
1.2.1 Global GLP-1 Agonist Injection Market Value Comparison by Type (2024-2030)
1.2.2 Short-acting Preparations
1.2.3 Long-acting Preparations
1.3 GLP-1 Agonist Injection by Application
1.3.1 Global GLP-1 Agonist Injection Market Value by Application (2024-2030)
1.3.2 Diabetes
1.3.3 Obesity
1.4 Global GLP-1 Agonist Injection Market Size Estimates and Forecasts
1.4.1 Global GLP-1 Agonist Injection Revenue 2019-2030
1.4.2 Global GLP-1 Agonist Injection Sales 2019-2030
1.4.3 Global GLP-1 Agonist Injection Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 GLP-1 Agonist Injection Market Competition by Manufacturers
2.1 Global GLP-1 Agonist Injection Sales Market Share by Manufacturers (2019-2024)
2.2 Global GLP-1 Agonist Injection Revenue Market Share by Manufacturers (2019-2024)
2.3 Global GLP-1 Agonist Injection Average Price by Manufacturers (2019-2024)
2.4 Global Key Players of GLP-1 Agonist Injection, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of GLP-1 Agonist Injection, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of GLP-1 Agonist Injection, Product Type & Application
2.7 Global Key Manufacturers of GLP-1 Agonist Injection, Date of Enter into This Industry
2.8 Global GLP-1 Agonist Injection Market Competitive Situation and Trends
2.8.1 Global GLP-1 Agonist Injection Market Concentration Rate
2.8.2 The Global 5 and 10 Largest GLP-1 Agonist Injection Players Market Share by Revenue
2.8.3 Global GLP-1 Agonist Injection Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global GLP-1 Agonist Injection Market Scenario by Region
3.1 Global GLP-1 Agonist Injection Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global GLP-1 Agonist Injection Sales by Region: 2019-2030
3.2.1 Global GLP-1 Agonist Injection Sales by Region: 2019-2024
3.2.2 Global GLP-1 Agonist Injection Sales by Region: 2025-2030
3.3 Global GLP-1 Agonist Injection Revenue by Region: 2019-2030
3.3.1 Global GLP-1 Agonist Injection Revenue by Region: 2019-2024
3.3.2 Global GLP-1 Agonist Injection Revenue by Region: 2025-2030
3.4 North America GLP-1 Agonist Injection Market Facts & Figures by Country
3.4.1 North America GLP-1 Agonist Injection Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America GLP-1 Agonist Injection Sales by Country (2019-2030)
3.4.3 North America GLP-1 Agonist Injection Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe GLP-1 Agonist Injection Market Facts & Figures by Country
3.5.1 Europe GLP-1 Agonist Injection Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe GLP-1 Agonist Injection Sales by Country (2019-2030)
3.5.3 Europe GLP-1 Agonist Injection Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific GLP-1 Agonist Injection Market Facts & Figures by Region
3.6.1 Asia Pacific GLP-1 Agonist Injection Market Size by Region: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific GLP-1 Agonist Injection Sales by Region (2019-2030)
3.6.3 Asia Pacific GLP-1 Agonist Injection Revenue by Region (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America GLP-1 Agonist Injection Market Facts & Figures by Country
3.7.1 Latin America GLP-1 Agonist Injection Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America GLP-1 Agonist Injection Sales by Country (2019-2030)
3.7.3 Latin America GLP-1 Agonist Injection Revenue by Country
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa GLP-1 Agonist Injection Market Facts & Figures by Country
3.8.1 Middle East and Africa GLP-1 Agonist Injection Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa GLP-1 Agonist Injection Sales by Country (2019-2030)
3.8.3 Middle East and Africa GLP-1 Agonist Injection Revenue by Country
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global GLP-1 Agonist Injection Sales by Type (2019-2030)
4.1.1 Global GLP-1 Agonist Injection Sales by Type (2019-2024)
4.1.2 Global GLP-1 Agonist Injection Sales by Type (2025-2030)
4.1.3 Global GLP-1 Agonist Injection Sales Market Share by Type (2019-2030)
4.2 Global GLP-1 Agonist Injection Revenue by Type (2019-2030)
4.2.1 Global GLP-1 Agonist Injection Revenue by Type (2019-2024)
4.2.2 Global GLP-1 Agonist Injection Revenue by Type (2025-2030)
4.2.3 Global GLP-1 Agonist Injection Revenue Market Share by Type (2019-2030)
4.3 Global GLP-1 Agonist Injection Price by Type (2019-2030)
5 Segment by Application
5.1 Global GLP-1 Agonist Injection Sales by Application (2019-2030)
5.1.1 Global GLP-1 Agonist Injection Sales by Application (2019-2024)
5.1.2 Global GLP-1 Agonist Injection Sales by Application (2025-2030)
5.1.3 Global GLP-1 Agonist Injection Sales Market Share by Application (2019-2030)
5.2 Global GLP-1 Agonist Injection Revenue by Application (2019-2030)
5.2.1 Global GLP-1 Agonist Injection Revenue by Application (2019-2024)
5.2.2 Global GLP-1 Agonist Injection Revenue by Application (2025-2030)
5.2.3 Global GLP-1 Agonist Injection Revenue Market Share by Application (2019-2030)
5.3 Global GLP-1 Agonist Injection Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Novo Nordisk
6.1.1 Novo Nordisk Company Information
6.1.2 Novo Nordisk Description and Business Overview
6.1.3 Novo Nordisk GLP-1 Agonist Injection Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Novo Nordisk GLP-1 Agonist Injection Product Portfolio
6.1.5 Novo Nordisk Recent Developments/Updates
6.2 Eli Lilly
6.2.1 Eli Lilly Company Information
6.2.2 Eli Lilly Description and Business Overview
6.2.3 Eli Lilly GLP-1 Agonist Injection Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Eli Lilly GLP-1 Agonist Injection Product Portfolio
6.2.5 Eli Lilly Recent Developments/Updates
6.3 AstraZeneca
6.3.1 AstraZeneca Company Information
6.3.2 AstraZeneca Description and Business Overview
6.3.3 AstraZeneca GLP-1 Agonist Injection Sales, Revenue and Gross Margin (2019-2024)
6.3.4 AstraZeneca GLP-1 Agonist Injection Product Portfolio
6.3.5 AstraZeneca Recent Developments/Updates
6.4 GSK
6.4.1 GSK Company Information
6.4.2 GSK Description and Business Overview
6.4.3 GSK GLP-1 Agonist Injection Sales, Revenue and Gross Margin (2019-2024)
6.4.4 GSK GLP-1 Agonist Injection Product Portfolio
6.4.5 GSK Recent Developments/Updates
6.5 Sanofi
6.5.1 Sanofi Company Information
6.5.2 Sanofi Description and Business Overview
6.5.3 Sanofi GLP-1 Agonist Injection Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Sanofi GLP-1 Agonist Injection Product Portfolio
6.5.5 Sanofi Recent Developments/Updates
6.6 Amylin
6.6.1 Amylin Company Information
6.6.2 Amylin Description and Business Overview
6.6.3 Amylin GLP-1 Agonist Injection Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Amylin GLP-1 Agonist Injection Product Portfolio
6.6.5 Amylin Recent Developments/Updates
6.7 Huadong Medicine
6.7.1 Huadong Medicine Company Information
6.7.2 Huadong Medicine Description and Business Overview
6.7.3 Huadong Medicine GLP-1 Agonist Injection Sales, Revenue and Gross Margin (2019-2024)
6.7.4 Huadong Medicine GLP-1 Agonist Injection Product Portfolio
6.7.5 Huadong Medicine Recent Developments/Updates
6.8 Shanghai Benemae Pharmaceutical Corporation
6.8.1 Shanghai Benemae Pharmaceutical Corporation Company Information
6.8.2 Shanghai Benemae Pharmaceutical Corporation Description and Business Overview
6.8.3 Shanghai Benemae Pharmaceutical Corporation GLP-1 Agonist Injection Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Shanghai Benemae Pharmaceutical Corporation GLP-1 Agonist Injection Product Portfolio
6.8.5 Shanghai Benemae Pharmaceutical Corporation Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 GLP-1 Agonist Injection Industry Chain Analysis
7.2 GLP-1 Agonist Injection Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 GLP-1 Agonist Injection Production Mode & Process
7.4 GLP-1 Agonist Injection Sales and Marketing
7.4.1 GLP-1 Agonist Injection Sales Channels
7.4.2 GLP-1 Agonist Injection Distributors
7.5 GLP-1 Agonist Injection Customers
8 GLP-1 Agonist Injection Market Dynamics
8.1 GLP-1 Agonist Injection Industry Trends
8.2 GLP-1 Agonist Injection Market Drivers
8.3 GLP-1 Agonist Injection Market Challenges
8.4 GLP-1 Agonist Injection Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global GLP-1 Agonist Injection Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global GLP-1 Agonist Injection Market Value by Application (2024-2030) & (US$ Million)
Table 3. Global GLP-1 Agonist Injection Market Competitive Situation by Manufacturers in 2023
Table 4. Global GLP-1 Agonist Injection Sales (K Dose) of Key Manufacturers (2019-2024)
Table 5. Global GLP-1 Agonist Injection Sales Market Share by Manufacturers (2019-2024)
Table 6. Global GLP-1 Agonist Injection Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global GLP-1 Agonist Injection Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market GLP-1 Agonist Injection Average Price (US$/Dose) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of GLP-1 Agonist Injection, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of GLP-1 Agonist Injection, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of GLP-1 Agonist Injection, Product Type & Application
Table 12. Global Key Manufacturers of GLP-1 Agonist Injection, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global GLP-1 Agonist Injection by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in GLP-1 Agonist Injection as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global GLP-1 Agonist Injection Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global GLP-1 Agonist Injection Sales by Region (2019-2024) & (K Dose)
Table 18. Global GLP-1 Agonist Injection Sales Market Share by Region (2019-2024)
Table 19. Global GLP-1 Agonist Injection Sales by Region (2025-2030) & (K Dose)
Table 20. Global GLP-1 Agonist Injection Sales Market Share by Region (2025-2030)
Table 21. Global GLP-1 Agonist Injection Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global GLP-1 Agonist Injection Revenue Market Share by Region (2019-2024)
Table 23. Global GLP-1 Agonist Injection Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global GLP-1 Agonist Injection Revenue Market Share by Region (2025-2030)
Table 25. North America GLP-1 Agonist Injection Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America GLP-1 Agonist Injection Sales by Country (2019-2024) & (K Dose)
Table 27. North America GLP-1 Agonist Injection Sales by Country (2025-2030) & (K Dose)
Table 28. North America GLP-1 Agonist Injection Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America GLP-1 Agonist Injection Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe GLP-1 Agonist Injection Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe GLP-1 Agonist Injection Sales by Country (2019-2024) & (K Dose)
Table 32. Europe GLP-1 Agonist Injection Sales by Country (2025-2030) & (K Dose)
Table 33. Europe GLP-1 Agonist Injection Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe GLP-1 Agonist Injection Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific GLP-1 Agonist Injection Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific GLP-1 Agonist Injection Sales by Region (2019-2024) & (K Dose)
Table 37. Asia Pacific GLP-1 Agonist Injection Sales by Region (2025-2030) & (K Dose)
Table 38. Asia Pacific GLP-1 Agonist Injection Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific GLP-1 Agonist Injection Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America GLP-1 Agonist Injection Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America GLP-1 Agonist Injection Sales by Country (2019-2024) & (K Dose)
Table 42. Latin America GLP-1 Agonist Injection Sales by Country (2025-2030) & (K Dose)
Table 43. Latin America GLP-1 Agonist Injection Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America GLP-1 Agonist Injection Revenue Market Share by Country (2019-2024)
Table 45. Middle East and Africa GLP-1 Agonist Injection Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East and Africa GLP-1 Agonist Injection Sales by Country (2019-2024) & (K Dose)
Table 47. Middle East and Africa GLP-1 Agonist Injection Sales by Country (2025-2030) & (K Dose)
Table 48. Middle East and Africa GLP-1 Agonist Injection Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East and Africa GLP-1 Agonist Injection Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global GLP-1 Agonist Injection Sales (K Dose) by Type (2019-2024)
Table 51. Global GLP-1 Agonist Injection Sales (K Dose) by Type (2025-2030)
Table 52. Global GLP-1 Agonist Injection Sales Market Share by Type (2019-2024)
Table 53. Global GLP-1 Agonist Injection Sales Market Share by Type (2025-2030)
Table 54. Global GLP-1 Agonist Injection Revenue (US$ Million) by Type (2019-2024)
Table 55. Global GLP-1 Agonist Injection Revenue (US$ Million) by Type (2025-2030)
Table 56. Global GLP-1 Agonist Injection Revenue Market Share by Type (2019-2024)
Table 57. Global GLP-1 Agonist Injection Revenue Market Share by Type (2025-2030)
Table 58. Global GLP-1 Agonist Injection Price (US$/Dose) by Type (2019-2024)
Table 59. Global GLP-1 Agonist Injection Price (US$/Dose) by Type (2025-2030)
Table 60. Global GLP-1 Agonist Injection Sales (K Dose) by Application (2019-2024)
Table 61. Global GLP-1 Agonist Injection Sales (K Dose) by Application (2025-2030)
Table 62. Global GLP-1 Agonist Injection Sales Market Share by Application (2019-2024)
Table 63. Global GLP-1 Agonist Injection Sales Market Share by Application (2025-2030)
Table 64. Global GLP-1 Agonist Injection Revenue (US$ Million) by Application (2019-2024)
Table 65. Global GLP-1 Agonist Injection Revenue (US$ Million) by Application (2025-2030)
Table 66. Global GLP-1 Agonist Injection Revenue Market Share by Application (2019-2024)
Table 67. Global GLP-1 Agonist Injection Revenue Market Share by Application (2025-2030)
Table 68. Global GLP-1 Agonist Injection Price (US$/Dose) by Application (2019-2024)
Table 69. Global GLP-1 Agonist Injection Price (US$/Dose) by Application (2025-2030)
Table 70. Novo Nordisk Company Information
Table 71. Novo Nordisk Description and Business Overview
Table 72. Novo Nordisk GLP-1 Agonist Injection Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 73. Novo Nordisk GLP-1 Agonist Injection Product
Table 74. Novo Nordisk Recent Developments/Updates
Table 75. Eli Lilly Company Information
Table 76. Eli Lilly Description and Business Overview
Table 77. Eli Lilly GLP-1 Agonist Injection Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 78. Eli Lilly GLP-1 Agonist Injection Product
Table 79. Eli Lilly Recent Developments/Updates
Table 80. AstraZeneca Company Information
Table 81. AstraZeneca Description and Business Overview
Table 82. AstraZeneca GLP-1 Agonist Injection Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 83. AstraZeneca GLP-1 Agonist Injection Product
Table 84. AstraZeneca Recent Developments/Updates
Table 85. GSK Company Information
Table 86. GSK Description and Business Overview
Table 87. GSK GLP-1 Agonist Injection Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 88. GSK GLP-1 Agonist Injection Product
Table 89. GSK Recent Developments/Updates
Table 90. Sanofi Company Information
Table 91. Sanofi Description and Business Overview
Table 92. Sanofi GLP-1 Agonist Injection Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 93. Sanofi GLP-1 Agonist Injection Product
Table 94. Sanofi Recent Developments/Updates
Table 95. Amylin Company Information
Table 96. Amylin Description and Business Overview
Table 97. Amylin GLP-1 Agonist Injection Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 98. Amylin GLP-1 Agonist Injection Product
Table 99. Amylin Recent Developments/Updates
Table 100. Huadong Medicine Company Information
Table 101. Huadong Medicine Description and Business Overview
Table 102. Huadong Medicine GLP-1 Agonist Injection Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 103. Huadong Medicine GLP-1 Agonist Injection Product
Table 104. Huadong Medicine Recent Developments/Updates
Table 105. Shanghai Benemae Pharmaceutical Corporation Company Information
Table 106. Shanghai Benemae Pharmaceutical Corporation Description and Business Overview
Table 107. Shanghai Benemae Pharmaceutical Corporation GLP-1 Agonist Injection Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 108. Shanghai Benemae Pharmaceutical Corporation GLP-1 Agonist Injection Product
Table 109. Shanghai Benemae Pharmaceutical Corporation Recent Developments/Updates
Table 110. Key Raw Materials Lists
Table 111. Raw Materials Key Suppliers Lists
Table 112. GLP-1 Agonist Injection Distributors List
Table 113. GLP-1 Agonist Injection Customers List
Table 114. GLP-1 Agonist Injection Market Trends
Table 115. GLP-1 Agonist Injection Market Drivers
Table 116. GLP-1 Agonist Injection Market Challenges
Table 117. GLP-1 Agonist Injection Market Restraints
Table 118. Research Programs/Design for This Report
Table 119. Key Data Information from Secondary Sources
Table 120. Key Data Information from Primary Sources
Table 121. Authors List of This Report
List of Figures
Figure 1. Product Picture of GLP-1 Agonist Injection
Figure 2. Global GLP-1 Agonist Injection Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global GLP-1 Agonist Injection Market Share by Type: 2023 & 2030
Figure 4. Short-acting Preparations Product Picture
Figure 5. Long-acting Preparations Product Picture
Figure 6. Global GLP-1 Agonist Injection Market Value by Application (2024-2030) & (US$ Million)
Figure 7. Global GLP-1 Agonist Injection Market Share by Application: 2023 & 2030
Figure 8. Diabetes
Figure 9. Obesity
Figure 10. Global GLP-1 Agonist Injection Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 11. Global GLP-1 Agonist Injection Market Size (2019-2030) & (US$ Million)
Figure 12. Global GLP-1 Agonist Injection Sales (2019-2030) & (K Dose)
Figure 13. Global GLP-1 Agonist Injection Average Price (US$/Dose) & (2019-2030)
Figure 14. GLP-1 Agonist Injection Report Years Considered
Figure 15. GLP-1 Agonist Injection Sales Share by Manufacturers in 2023
Figure 16. Global GLP-1 Agonist Injection Revenue Share by Manufacturers in 2023
Figure 17. Global 5 and 10 Largest GLP-1 Agonist Injection Players: Market Share by Revenue in GLP-1 Agonist Injection in 2023
Figure 18. GLP-1 Agonist Injection Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 19. Global GLP-1 Agonist Injection Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 20. North America GLP-1 Agonist Injection Sales Market Share by Country (2019-2030)
Figure 21. North America GLP-1 Agonist Injection Revenue Market Share by Country (2019-2030)
Figure 22. United States GLP-1 Agonist Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 23. Canada GLP-1 Agonist Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 24. Europe GLP-1 Agonist Injection Sales Market Share by Country (2019-2030)
Figure 25. Europe GLP-1 Agonist Injection Revenue Market Share by Country (2019-2030)
Figure 26. Germany GLP-1 Agonist Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 27. France GLP-1 Agonist Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 28. U.K. GLP-1 Agonist Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 29. Italy GLP-1 Agonist Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 30. Russia GLP-1 Agonist Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 31. Asia Pacific GLP-1 Agonist Injection Sales Market Share by Region (2019-2030)
Figure 32. Asia Pacific GLP-1 Agonist Injection Revenue Market Share by Region (2019-2030)
Figure 33. China GLP-1 Agonist Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 34. Japan GLP-1 Agonist Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 35. South Korea GLP-1 Agonist Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 36. India GLP-1 Agonist Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 37. Australia GLP-1 Agonist Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 38. China Taiwan GLP-1 Agonist Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. Southeast Asia GLP-1 Agonist Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. Latin America GLP-1 Agonist Injection Sales Market Share by Country (2019-2030)
Figure 41. Mexico GLP-1 Agonist Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. Brazil GLP-1 Agonist Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 43. Argentina GLP-1 Agonist Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 44. Colombia GLP-1 Agonist Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 45. Middle East and Africa GLP-1 Agonist Injection Sales Market Share by Country (2019-2030)
Figure 46. Middle East and Africa GLP-1 Agonist Injection Revenue Market Share by Country (2019-2030)
Figure 47. Turkey GLP-1 Agonist Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 48. Saudi Arabia GLP-1 Agonist Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 49. UAE GLP-1 Agonist Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 50. Global Sales Market Share of GLP-1 Agonist Injection by Type (2019-2030)
Figure 51. Global Revenue Market Share of GLP-1 Agonist Injection by Type (2019-2030)
Figure 52. Global GLP-1 Agonist Injection Price (US$/Dose) by Type (2019-2030)
Figure 53. Global Sales Market Share of GLP-1 Agonist Injection by Application (2019-2030)
Figure 54. Global Revenue Market Share of GLP-1 Agonist Injection by Application (2019-2030)
Figure 55. Global GLP-1 Agonist Injection Price (US$/Dose) by Application (2019-2030)
Figure 56. GLP-1 Agonist Injection Value Chain
Figure 57. GLP-1 Agonist Injection Production Process
Figure 58. Channels of Distribution (Direct Vs Distribution)
Figure 59. Bottom-up and Top-down Approaches for This Report
Figure 60. Data Triangulation
Figure 61. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
